Search

Your search keyword '"Biswas, Ahitagni"' showing total 320 results
Start Over Author "Biswas, Ahitagni"
320 results on '"Biswas, Ahitagni"'

5. Successful multimodality management of extrarenal extracranial malignant rhabdoid tumour of the left sciatic nerve mimicking a neurofibroma.

Author

Biswas, Ahitagni, Ramdulari, Anjali V., Thakur, Alok, Kumar, Amandeep, G. S., Anju, Jana, Manisha, and Suri, Vaishali

Subjects
*NERVE grafting, *SCIATIC nerve, *CONTRAST-enhanced magnetic resonance imaging, *PERIPHERAL nerve tumors, *NEUROFIBROMA
Abstract

Extrarenal extracranial malignant rhabdoid tumour (MRT) is a rare and highly aggressive tumour representing <1% of paediatric soft tissue malignancies. Only a few cases of MRT of the thigh arising from the sciatic nerve have been reported in medical literature to date. A 5-year-old girl presented with progressively increasing painless lump in the posterior aspect of the left thigh. A contrast-enhanced magnetic resonance imaging (MRI) of the left thigh showed a 4.7 × 5 × 10.5 cm well-marginated, lobulated, homogeneously enhancing lesion in the posterior compartment of the left thigh along the course of the sciatic nerve. She underwent en bloc excision of the left sciatic nerve tumour and end-to-end anastomosis of the left sciatic nerve with a right sural nerve graft. Histopathological and immunohistochemical examination of the surgical specimen revealed a malignant rhabdoid tumour. INI-1 immunoexpression was lost in the tumour cells. The metastatic workup was essentially normal. Subsequently, she received post-operative radiotherapy to the tumour bed (50.4 Gray in 28 fractions over 5.5 weeks) followed by six cycles of multiagent chemotherapy with ICE (Ifosfamide, Carboplatin, and Etoposide) regimen. On the last follow-up visit, 20 months after surgery, she was in complete clinical and radiological response. Aggressive multimodality management comprising radical resection of tumour, post-operative radiotherapy to the tumour bed, and multiagent chemotherapy with ICE regimen can lead to favourable outcomes in patients with this rare tumour. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

7. Treatment outcomes in patients with Ewing sarcoma of the spine in a resource-challenged setting: 17-year experience from a single center in India

Author

Sasi, Archana, primary, Chitikela, Sindhura, additional, Ganguly, Shuvadeep, additional, Biswas, Bivas, additional, Pushpam, Deepam, additional, Kumar, Akash, additional, Khan, Shah Alam, additional, Kumar, Venkatesan Sampath, additional, Kale, Shashank Sharad, additional, Biswas, Ahitagni, additional, Barwad, Adarsh, additional, Mridha, Asit Ranjan, additional, Thulkar, Sanjay, additional, and Bakhshi, Sameer, additional

Published
2024
Full Text
View/download PDF

15. Extramedullary Relapse of B Cell Acute Lymphoblastic Leukemia in Bilateral Breasts Treated with Whole Breast Radiotherapy.

Author

Ghosh, Vivek, Roy, Swarnaditya, Dhamija, Ekta, Rathore, Ruchi, Kumar, Lalit, and Biswas, Ahitagni

Subjects
HOMOGRAFTS, LYMPHOBLASTIC leukemia, B cell lymphoma, CANCER relapse, MAMMOGRAMS, DIFFERENTIAL diagnosis, TREATMENT effectiveness, CELLS, RADIOTHERAPY, HEMATOPOIETIC stem cell transplantation, BREAST tumors
Abstract

Isolated extramedullary relapse of acute lymphoblastic leukemia (ALL) in the breast is extremely rare. We herein report a case of a 38-year-old female with B cell ALL, who had isolated extramedullary relapse initially in the left breast and subsequently in the right breast, 3 and 4 years, respectively, after hematopoietic allogenic stem cell transplantation. She was successfully salvaged with bilateral whole breast radiotherapy, 24 Gy/12 fractions/2.5 weeks. This brief report highlights the importance of awareness of extramedullary leukemic relapse in the breast as one of the differential diagnoses of breast masses in the context of ALL. Since these tumors are extremely radioresponsive, radiation therapy is a safe and effective treatment option for isolated extramedullary relapse of ALL in the breast. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

16. Role of circulating tumour cells (CTCs) in recurrent/metastatic head and neck squamous cell carcinoma (HNSCC)

Author

Kanchan Baa, Annie, primary, Sharma, Atul, additional, Bhaskar, Suman, additional, Biswas, Ahitagni, additional, Thakar, Alok, additional, Kumar, Rajeev, additional, Jayant, Sreeja, additional, Aland, Gourishankar, additional, D’Souza, Alain, additional, Jadhav, Vikas, additional, Bharde, Atul, additional, Khandare, Jayant, additional, and Pramanik, Raja, additional

Published
2023
Full Text
View/download PDF

19. A prospective phase II trial of response adapted whole brain radiotherapy after high dose methotrexate based chemotherapy in patients with newly diagnosed primary central nervous system lymphoma-analysis of acute toxicity profile and early clinical outcome

Author

Adhikari, Narayan, Biswas, Ahitagni, Gogia, Ajay, Sahoo, Ranjit Kumar, Garg, Ajay, Nehra, Ashima, Sharma, Mehar Chand, Bhasker, Suman, Singh, Manmohan, Sreenivas, Vishnubhatla, Chawla, Rohan, Joshi, Garima, Kumar, Lalit, and Chander, Subhash

Published
2018
Full Text
View/download PDF

20. Real World Presentation and Treatment Outcomes with a Predominant Induction Chemotherapy Based Approach in Nasopharyngeal Carcinoma: A Sixteen Year Report from a Teaching Hospital in India

Author

Gogi, Ramana, primary, Sharma, Aparna, additional, Sharma, Atul, additional, Mohanti, BK, additional, Pramanik, Raja, additional, Bhasker, Suman, additional, Biswas, Ahitagni, additional, Thakar, Alok, additional, Singh, Amit Chirom, additional, Sikka, Kapil, additional, Kumar, Rajeev, additional, Thulkar, Sanjay, additional, and Bahadur, Sudhir, additional

Published
2022
Full Text
View/download PDF

21. Efficacy and Safety of Percutaneous Radiological Gastrostomy (PRG) as a Rescue Measure for Enteral Feeding in Patients with Advanced Head, Neck, and Upper Digestive Malignancies

Author

Kumar, Mukesh, additional, Chahal, Anurag, additional, Malla, Sundeep, additional, Bharti, Sachidanand G., additional, Kumar, Sunil, additional, Biswas, Ahitagni, additional, Sahoo, Ranjit, additional, Pramanik, Raja, additional, Pathy, Sushmita, additional, Bhaskar, Suman, additional, Chandrashekhara, S.H., additional, Sreenivas, V., additional, and Thulkar, Sanjay, additional

Published
2022
Full Text
View/download PDF

26. Response to Neoadjuvant Chemotherapy and Outcomes in Children With Wilms Tumor With Caval Thrombus: A Single Center Experience

Author

Jain, Vishesh, primary, Krishnan, Nellai, additional, Agarwala, Sandeep, additional, Bishoi, Akshay Kumar, additional, Dhua, Anjan, additional, Bakhshi, Sameer, additional, Chauhan, Sandeep, additional, Biswas, Ahitagni, additional, Srinivas, Maddur, additional, Iyer, Venkateswaran K., additional, Jana, Manisha, additional, Kandasamy, Devasenathipathy, additional, Yadav, Devendra Kumar, additional, and Bajpai, Minu, additional

Published
2022
Full Text
View/download PDF

27. A feasibility study of EMF(erlotinib+methotrexate+5-fluorouracil) regimen in recurrent head and neck squamous cell carcinoma (HNSCC) and role of circulating tumour cells(CTCs) in assessment of outcomes.

Author

Baa, Annie, primary, Pramanik, Raja, additional, Sharma, Atul, additional, Biswas, Ahitagni, additional, JeeBharti, Sachidanand, additional, Singh, Mayank, additional, Kumar, Rajeev, additional, Gourishankar, Aland, additional, Jayant, Sreeja, additional, D'Souza, Alain, additional, Jadhav, Vikas, additional, and Khandare, Jayant, additional

Published
2022
Full Text
View/download PDF

29. Outcome of children with stage IV wilms tumor - Our experience of 15 years

Author

Jain, Vishesh, Dhua, Anjan, Agarwala, Sandeep, Bakhshi, Sameer, Srinivas, M., Iyer, Venkateswaran, Mathur, Sandeep, Jana, Manisha, Kandasamy, Devasenathipathy, Biswas, Ahitagni, Bhatnagar, Veereshwar, and Bajpai, Minu

Subjects
Vincristine, Chemotherapy, Nephroblastoma -- Prognosis, Genetic markers, Health
Abstract

Byline: Vishesh. Jain, Anjan. Dhua, Sandeep. Agarwala, Sameer. Bakhshi, M. Srinivas, Venkateswaran. Iyer, Sandeep. Mathur, Manisha. Jana, Devasenathipathy. Kandasamy, Ahitagni. Biswas, Veereshwar. Bhatnagar, Minu. Bajpai Context: Stage IV Wilms tumor [...]

Published
2020

32. Autologous stem cell transplant for multiple myeloma: Impact of melphalan dose on the transplant outcome.

Author

Kumar, Lalit, Sahoo, Ranjit Kumar, Kumar, Sudhir, Baa, Annie K., Tansir, Ghazal, Pathak, Neha, Malik, Prabhat S., Sharma, Om Dutt, Mathew, Anisha, Jha, Ankit, Gupta, Ritu, Sharma, Atul, Biswas, Ahitagni, Kumar, Rakesh, Thulkar, Sanjay, Malik, Soumyaranjan, and Dutt, Ashish

Subjects
STEM cell transplantation, TREATMENT effectiveness, MULTIPLE myeloma, MELPHALAN, PROGRESSION-free survival
Abstract

We evaluated impact of melphalan dose on transplant outcomes for multiple myeloma. Between 1995 and 2019 459 consecutive patients received a transplant; 69(15%) received melphalan ≤150 mg/m2 (Mel 150 cohort) and 390 (85%) melphalan 200 mg/m2 (MEL 200 cohort). The primary outcome was overall survival (OS) from the date of transplant. Progression-free survival (PFS), engraftment, transplant response, and cumulative relapse at 2 years were secondary outcome measures. Patients in Mel 150 cohort had adverse clinical and laboratory parameters at base line. Transplant response was better for Mel 200 cohort (p < 0.024). Median OS at a median follow-up of 88 months was similar in the two cohorts; 100 Vs 102 months (Mel 200), p = 0.817. Median PFS (60.0 Vs 53 months, p = 0.746), relapse at two years (32.4% Vs 30.9%, p = 0.745) and grade 3-4 mucositis (p = 0.823) were similar. Initial treatment prepares patients better for subsequent similar transplant outcomes despite differences in baseline characteristics. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

33. Real World Presentation and Treatment Outcomes with a Predominant Induction Chemotherapy Based Approach in Nasopharyngeal Carcinoma: A Sixteen Year Report from a Teaching Hospital in India.

Author

Gogi, Ramana, Sharma, Aparna, Sharma, Atul, Mohanti, BK, Pramanik, Raja, Bhasker, Suman, Biswas, Ahitagni, Thakar, Alok, Singh, Amit Chirom, Sikka, Kapil, Kumar, Rajeev, Thulkar, Sanjay, and Bahadur, Sudhir

Subjects
NASOPHARYNX cancer, DISEASE progression, ACADEMIC medical centers, CANCER relapse, TREATMENT effectiveness, TUMOR classification, DESCRIPTIVE statistics, INDUCTION chemotherapy, DRUG toxicity
Abstract

Nasopharyngeal carcinoma (NPC) is a rare malignancy in India except in north-eastern states. We present our institutional experience of 16 years highlighting management, outcomes, responses and toxicities. NPC patients registered at our center during the period of 2000–2015. The primary objective of the study was to assess the overall survival (OS). Secondary outcome included determinations of response rates, progression free survival (PFS) and to assess treatment-related toxicity (CTCAE v4.0). Institute ethics committee approval was obtained prior to initiation of this study. Data was retrieved from complete records of 222 patients out of 390 registered during study period. There were 163 males (73.4%) and 59 females (26.6%) with a male to female ratio of 2.8:1. The median age was 35 years (range 6–73). Only 5.6% (n = 12) presented in early-stage disease (stage I and II) while 89.6% (n = 199) were advanced stage (stage III, IVA, IVB). Five patients (2.2%) presented as metastatic disease. Majority of patients were treated with induction chemotherapy followed by concurrent chemoradiation (CCRT) {76.1%, n = 169}. Relapses were documented in 10.4% patients. 5% patients had loco-regional relapse while distant metastases were seen in 4% patients. The 3-year PFS and OS rates are 60.9% and 68.4%, respectively. Achieving a CR predicted superior OS on multivariate analysis. NPC is a rare malignancy and majority presented with advanced stages. This data outlines our experience and outcomes with a predominantly induction chemotherapy followed by definitive CCRT based approach. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

38. Risk based and response adapted radiation therapy for children and adolescents with newly diagnosed advanced stage Hodgkin lymphoma treated with ABVD chemotherapy: a report from the Indian pediatric oncology group study InPOG-HL-15-01

Author

Jain, Sandeep, primary, Bakhshi, Sameer, additional, Seth, Rachna, additional, Verma, Nishant, additional, Singh, Manisha, additional, Mahajan, Amita, additional, Radhakrishnan, Venkatraman, additional, Mandal, Piali, additional, Arora, Ramandeep, additional, Dinand, Veronique, additional, Kalra, Manas, additional, Sharma, Anurag, additional, Taluja, Ankit, additional, Thulkar, Sanjay, additional, Biswas, Ahitagni, additional, and Chandra, Jagdish, additional

Published
2021
Full Text
View/download PDF

42. Poster: ABCL-321: Clinicopathological Profile of Gastrointestinal Lymphoma Diagnosed Over a Period of 6-Years: A Tertiary Care Center Experience

Author

Ramteke, Prashant, primary, Jain, Surabhi, additional, Meena, Shweta, additional, Mandal, Trisha, additional, Das, Prasanjit, additional, Yadav, Rajni, additional, Sharma, Mehar Chand, additional, Gogia, Ajay, additional, Parmanik, Raja, additional, Sharma, Atul, additional, Bakhshi, Sameer, additional, Mahapatra, Manoranjan, additional, Biswas, Ahitagni, additional, Kumar, Lalit, additional, and Mallick, Saumyaranjan, additional

Published
2021
Full Text
View/download PDF

43. ABCL-321: Clinicopathological Profile of Gastrointestinal Lymphoma Diagnosed Over a Period of 6-Years: A Tertiary Care Center Experience

Author

Ramteke, Prashant, primary, Jain, Surabhi, additional, Meena, Shweta, additional, Mandai, Trisha, additional, Das, Prasanjit, additional, Yadav, Rajni, additional, Sharma, Mehar Chand, additional, Gogia, Ajay, additional, Parmanik, Raja, additional, Sharma, Atul, additional, Bakhshi, Sameer, additional, Mahapatra, Manoranjan, additional, Biswas, Ahitagni, additional, Kumar, Lalit, additional, and Mallick, Saumyaranjan, additional

Published
2021
Full Text
View/download PDF

47. Oral Cancer in the Indian Subcontinent‐Survival Outcomes and Risk Factors with Primary Surgery

Author

Thakar, Alok, primary, Thakur, Rishikesh, additional, Kakkar, Aanchal, additional, Malhotra, Rajeev Kumar, additional, Singh, Chirom Amit, additional, Sikka, Kapil, additional, Kumar, Rajeev, additional, Pramanik, Raja, additional, Biswas, Ahitagni, additional, Bhalla, Ashu Seith, additional, Bhaskar, Suman, additional, and Sharma, Atul, additional

Published
2021
Full Text
View/download PDF

50. Risk based and response adapted radiation therapy for children and adolescents with newly diagnosed advanced stage Hodgkin lymphoma treated with ABVD chemotherapy: a report from the Indian pediatric oncology group study InPOG-HL-15-01.

Author

Jain, Sandeep, Bakhshi, Sameer, Seth, Rachna, Verma, Nishant, Singh, Manisha, Mahajan, Amita, Radhakrishnan, Venkatraman, Mandal, Piali, Arora, Ramandeep, Dinand, Veronique, Kalra, Manas, Sharma, Anurag, Taluja, Ankit, Thulkar, Sanjay, Biswas, Ahitagni, and Chandra, Jagdish

Subjects
HODGKIN'S disease, PEDIATRIC oncology, RADIOTHERAPY, CANCER chemotherapy, TEENAGERS
Abstract

This multi-centric prospective study (InPOG-HL-15-01) assessed epidemiological, clinical and outcome data of advanced stage Hodgkin Lymphoma (IIB, III and IV) in children and adolescents (N = 262). Chemotherapy regimen was ABVD (doxorubicin, bleomycin, vinblastine, dacarbazine) and radiotherapy (RT) was restricted to patients with bulky disease at diagnosis or with suboptimal response at early response assessment (ERA). ERA revealed complete response in 175 (68.1%), partial response in 77 (29.9%), stable disease in 2 (0.8%), and progressive disease in 3 (1.2%) patients. RT was administered to 111 (97 bulky disease, 14 suboptimal response) patients. Five-year event free (EFS) and overall survival for the whole cohort was 81.1% and 90.8% respectively. On multivariate analysis, the only statistically significant predictor of EFS was use of RT (89% versus 74.2%; p-value <0.001). This study reinforces the benefit of consolidative RT in bulky disease and in those with suboptimal response at ERA on an ABVD backbone. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results